New Taysha CEO Sean Nolan (L) and former CEO RA Session II
Taysha CEO steps down after patent fights with patient families, job cuts
Taysha Gene Therapies CEO RA Session II has resigned following a turbulent year in which the company shelved most of its rare disease pipeline and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
